EI-001 antibody drug for adults with non-segmental vitiligo
Tests EI-001 against a placebo in adults with non-segmental vitiligo.
Key facts
- Who runs it
- Elixiron Immunotherapeutics (Hong Kong) Ltd.
- Where
- Hollywood, Houston, Huntington Beach, Lorain, Mayfield Heights, and Worcester, United StatesSee the 6 sitesAlso in 1 other country, 2 sites
- Trial code
- Registry title
- Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 45 people, planned
- Started
- 30 Dec 2025
- Expected to end
- 30 Sept 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- EI-001
- Placebo
- Record updated
- 2 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with non-segmental vitiligo who did not respond well enough to usual treatments or cannot use them. It tests EI-001 against a placebo.
- Age
- 18-65 years
- Sex
- All sexes
- Disease stage
- Non-segmental vitiligo diagnosed by a doctor for at least 3 months. Facial BSA ≥ 0.5% and F-VASI ≥ 0.5. Total BSA between 5% and 60% and T-VASI ≥ 5. BMI 18-38 kg/m² and weight ≥ 40 kg (88 lb).
- Earlier treatment
- Not enough response to approved treatments: topical therapy (e.g., corticosteroids, calcineurin inhibitors, or JAK inhibitors) ≥ 3 months, phototherapy ≥ 6 months, or oral therapy ≥ 3 months. Or unable to use these treatments for medical reasons or intolerance. Must stop all vitiligo treatments during the study. Must complete zoster vaccination before Day 1 if not vaccinated.
Main reasons for not taking part
- Segmental vitiligo or other skin color loss disorders, or ≥30% white hair on face or body
- Pregnancy or breastfeeding
- Recent vitiligo treatments, surgical treatments, depigmenting agents or high-dose steroids
- Heart problems, abnormal chest X-ray, kidney problems or viral infections
- Allergy to EI-001 or its ingredients
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- Able to understand and voluntarily sign the informed consent form (ICF)
- Male or female, aged 18-65 years at the time of consent
- BMI 18-38 kg/m² and weight ≥ 40 kg at consent. Clinically diagnosed non-segmental vitiligo (NSV) for at least 3 months, and meets one of the following:
- Inadequate response to approved treatments:
- Topical therapy (e.g., corticosteroids, calcineurin inhibitors, or JAK inhibitors) ≥ 3 months,
- Phototherapy ≥ 6 months, or Oral therapy (e.g., corticosteroids, calcineurin inhibitors) ≥ 3 months
- Or unable to use these treatments due to contraindications, intolerance, or unsuitability
- Depigmentation extent meeting all of the following:; Facial BSA (F-BSA) ≥ 0.5%, Facial VASI (F-VASI) ≥ 0.5, Total BSA (T-BSA) between 5% and 60%, Total VASI (T-VASI) ≥ 5
- Agree to discontinue all vitiligo treatments from screening until final follow-up
- If not previously vaccinated against zoster, agree to complete vaccination before Day 1
- Contraception
- Not applicable to females of non-childbearing potential (surgically sterile or postmenopausal ≥12 months, confirmed by FSH at screening)
Who cannot take part
- Surgical treatments or depigmenting agents (e.g., monobenzone)
- High-dose steroids
- Prohibited prior therapies
- Non-eligible skin conditions: Other types of vitiligo (e.g., segmental) or other depigmentation disorders (e.g., piebaldism, leprosy, post-inflammatory hypopigmentation, tinea versicolor, etc.), or ≥30% leukotrichia on face or body
- Psychiatric risk
- Abnormal Medical conditions
- Cardiac abnormalities
- Renal impairment
- Viral infections:
- Hypersensitivity: Known allergy or severe reaction to EI-001 or its excipients
- Compliance concerns: Any condition that would make it difficult for the subject to follow the study schedule, receive treatment, attend visits, or could interfere with study objectives, data interpretation, or participant safety
- Clinically significant abnormal laboratory results at screening, per investigator judgment
- Recent vitiligo treatments
- Pregnancy or lactation
- Abnormal chest X-ray
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
Also in 1 other country, 2 sites
- Skin Care Research, LlcHollywood, United StatesContact: Jacklyn McFaydenTaking people
- Center for Clinical StudiesHouston, United StatesContact: Mario Guerrero Site CoordinatorTaking people
- Marvel Clinical ResearchHuntington Beach, United StatesContact: Matthew Campos Site CoordinatorTaking people
- Apex Clinical Research Center (Lorain)Lorain, United StatesContact: Caroline Matyas study coordinatorTaking people
- Apex Clinical Research Center, LLC (Mayfield)Mayfield Heights, United StatesContact: Dr. Garcia Principal InvestigatorTaking people
- U Mass Chan Medical SchoolWorcester, United StatesNo longer taking part
About the trial
What the trial wants to find out
The primary purpose of this study is to evaluate whether the drug EI-001 can help improve vitiligo symptoms. EI-001 is a novel antibody drug that affects the immune system to decrease uncontrolled inflammation. EI-001 has been investigated in human cell cultures, animal studies, and in a Phase 1 healthy volunteer study. The results so far show that EI-001 is a tolerable and potential new treatment for immune diseases such as vitiligo.
The 2 groups in the trial
- Drug: EI-001Treatment being tested
Treatment: EI-001
- Drug: PlaceboPlacebo, for comparison
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 2, Randomized, Double-Blind, Placebo-controlled Proof-of-Concept Study to Evaluate the Efficacy and Safety of EI-001 in Patients With Nonsegmental Vitiligo
- Plain-language title
- EI-001 antibody drug for adults with non-segmental vitiligoGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT07223229, who can take part
- Record updated
- 2 November 2026